You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Strontium ranelate reduced the risk of vertebral fractures in postmenopausal women with osteoporosis

https://doi.org/10.1136/ebm.9.5.149

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459–68.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In postmenopausal women with osteoporosis, is strontium ranelate more effective than placebo for reducing the risk of vertebral fractures?

    Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Geriatrics ★★★★★☆☆ Rheumatology ★★★★★★☆

    METHODS

    Embedded ImageDesign:

    randomised controlled trial.

    Embedded ImageAllocation:

    unclear.*

    Embedded ImageBlinding:

    blinded (patients and healthcare providers).*

    Embedded ImageFollow up period:

    3 years.

    Embedded ImageSetting:

    72 centres in 11 European countries and Australia.

    Embedded ImagePatients:

    1649 women who were ⩾50 years of age (mean age 69 y) and had been postmenopausal for ⩾5 years, had ⩾1 fracture confirmed by spinal radiography, and had a lumbar spine bone mineral density (BMD) ⩽0.840 g/cm2. Exclusion criteria were severe diseases or conditions that could interfere with bone metabolism or use of antiosteoporotic treatments (fluoride salts and bisphosphonates, oestrogen, calcitonin, or calcitriol).

    Embedded ImageIntervention:

    all …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • For correspondence: Dr P J Meunier, Edouard Herriot Hospital, Lyons, France. pierre.meunierlaennec.univ-lyon1.fr

    • Source of funding: Servier.